

REFERENCE ACKNOWLEDGMENT 2023 NHSN ANNUAL TRAINING

- Patient Safety Component: Pneumonia(PNEU) Surveillance
- Pediatric Ventilator-associated event (PedVAE) Surveillance

Jennifer Watkins, RN, BSN, MPH NHSN Protocol and Training Team


Ventilator Associated Event (VAE)
 Surveillance Guideline and Protocol Application (2024)
 Emily Witt, MPH
 NHSN Protocol and Training Team

2

PNEU SURVEILLANCE OPTIONS

- Available for in-plan reporting for mechanically ventilated patients in pediatric locations only (pedVAP)
- Available for off-plan reporting for any patient regardless of location, age, or ventilation status (for example a state reporting requirement, facility surveillance plan)
- Available for secondary BSI assignment in any patient regardless of location, age, or ventilation status.
 - Also, regardless of surveillance of VAE or PedVAE in the same location

3



4

PNU1 ALGORITHM (TABLE 1, PNEU PROTOCOL)

- PNU1 is 'clinically defined'-no laboratory test evidence required
- Required elements:
 - Imaging test evidence
- Signs/symptoms
- ► 3 sets of criteria:
 - Any patient-patients of any age, including infants and children
 - Alternative criteria-infants < 1 year old</p>
 - Alternative criteria-child > 1 year or < 12 years old</p>
- Age-specific criteria apply to PNU1 ONLY (cannot be used for PNU2 or PNU3)

TABLE 1: SPECIFIC SITE ALGORITHMS for Clinically Defined Pneumonia (PNU1) Two or more serial chest imaging test For **ANY PATIENT**, at least one of the following: results with at least one of the Fever (>38.0°C or > 100.4°F) following¹,²,¹ Leukopenia (<4000 WBC/mm³) or New and persistent OR Progressive and leukocytosis (≥12,000 WBC/mm³) persistent . For adults \geq 70 years old, altered mental Infiltrate status with no other recognized cause Consolidation Cavitation And at least two of the following: Pneumatoceles, in infants <1 year old New onset of purulent sputum³ or change in character of sputum⁴, or increased Note: In patients without underlying respiratory secretions, or increased pulmonary or cardiac disease (for example suctioning requirements respiratory distress syndrome, New onset or worsening cough, or dyspnea, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary or tachypnea⁵ Rales⁶ or bronchial breath sounds Worsening gas exchange (i.e., O_2 desaturation-PaO₂/FiO₂ \leq 240)⁷, increased oxygen requirements or ventilator demand) disease), one definitive imaging test result . is acceptable¹

TABLE 1: SPECIFIC SITE ALGORITHMS for Clinically Defined Pneumonia (PNU1)		
Imaging Test Evidence	Signs/symptoms	
Two or more serial chest imaging test results with at least one of the following ¹ 2, ¹⁶ : New and persistent OR Progressive and persistent: • Infiltrate • Consolidation • Cavitation • Pneumatoceles, in infants ≤1 year old	ALTERNATE CRITERIA: for infants ≤1 year old: Worsening gas exchange (i.e., 0, desaturation (for example pulse oximeter <94%), increased oxygen requirements or ventilator demand)	
Note: In patients <i>without</i> underlying pulmonary or cardiac disease (for example respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), one definitive imaging test result is acceptable ¹	 New onset of purulent sputum³ <u>or</u> change in character of sputum⁴, or increased respiratory secretions, or increased suctioning requirements Apnea, tachypnea⁵ nasal flaring with retraction of chest wall, or nasal flaring with grunting Wheezing, rales⁶ or rhonchi Cough Bradycardia (<100 beats/min) or tachycardia (>170 beats/min) 	

9


▶ PNU2 is comprised of:

Imaging test evidence

Signs/symptoms Laboratory evidence

▶ Split into 2 tables

No age-specific criteria for S/S



Two or more serial chest imaging test

New and persistent OR Progressive and

Pneumatoceles, in infants <1 year old

pulmonary or cardiac disease (for example •

bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary

disease), one definitive imaging test result

Note: In patients without underlying

respiratory distress syndrome.

results with at least one of the

following^{1,2,14}

persistent: • Infiltrate

Consolidation

Cavitation

is acceptable

10






TABLE 1: SPECIFIC SITE ALGORITHMS for Clinically Defined Pneumonia (PNU1)

.

.

ALTERNATE CRITERIA: for child > 1 year old or <

Fever (>38.0°C or > 100.4°F) or hypothermia

character of sputum⁴, or increased respiratory secretions, or increased suctioning

New onset of worsening cough, or dyspnea,

Worsening gas exchange (i.e., O_2 desaturation

{for example pulse oximeter <94%}, increased

oxygen requirements or ventilator demand)

12 years old, at least three of the following:

Leukopenia (<u><</u>4000 WBC/mm³) or

leukocytosis (>15,000 WBC/mm³) New onset of purulent sputum³ or change in

Rales⁶ or bronchial breath sounds

(< 36.0°C or <96.8°F)

or apnea, or tachypnea

requirements


PNU3 is for Immunocompromised patients

Immunocompromised definition in footnote #10 must be met in order to apply PNU3


▶ PNU3 is comprised of:

- Imaging test evidence
- ► S/S
- Laboratory evidence
- ▶ No age-specific criteria for S/S


Imaging Test Evidence Signs/Symptoms Laboratory					
maging test evidence woor more serial chest maging test results with at east one of the following ^{1,3} : tew and persistent OR rogressive and persistent: Infiltrate Consolidation Cavitation Pneumatoceles, in infants ≤1 year old dist: In patients without Inderlying pulmonary or ardiac disease (for example espiratory distress syndrome, ronchopulmonary dysplasia, ulmonary dema, or chronic bstructive pulmonary Issaes), on edenihtive maging test result is cceptable ¹	 Sign3 Symptoms Fever (38.0°C or >100.4°F) Leukopenia (<4000 WBC/mm³) or leukocytosis (<212.000 WBC/mm³) For adults 2:0 years old, altered mental status with no other recognized cause And at least one of the following: New onset of purulent spatum³ or change in character of sputum³, or increased respiratory secretions, or increased suctioning requirements New onset or worsening cough, or dyspnea, or tachynnea³ Rales³ or bronchial breath sounds Worsening gas exchange (i.e. O₂, destaturation-PaOJ/Flo2_2407), increased swgen requirements 	Laboratory L			




15



14







- <u>New or Progressive</u> is determined in comparison to prior imaging test findings
- ► New findings-eligible findings were not present in prior imaging
 - ▶ 3/10 imaging findings: lungs are clear
 - 3/12 imaging findings: infiltrates
- Progressive findings-eligible findings are worse in comparison to prior imaging
 - 3/10 imaging findings: infiltrates present
 - 3/12 imaging findings: increasing (worsening) infiltrates



- Persistence of findings of pneumonia in subsequent imaging test results is required
 - For patients <u>with</u> underlying cardiac or pulmonary disease (serial imaging)
 - For <u>all patients</u> when multiple temporally related imaging test results are available
- If <u>only one definitive</u> imaging test is available, it can satisfy the imaging requirement in the following situations only:
 - For POA determinations for all patients
 - For patients <u>without</u> underlying cardiac or pulmonary disease, when <u>no other</u> <u>imaging is available</u>

ELIGIBLE IMAGING FINDINGS

Definitive findings listed in the PNEU algorithms:

- Infiltrate
- Consolidation
 Cavitation
- Pneumatoceles, in infants <1 year old
- Pheumatoceles, in mants <1 year old</p>
- Alternative findings-footnote #2
 - Opacities, airspace disease, densities
- 2. Note that there are many ways of describing the imaging appearance of pneumonia. Examples include, but are not limited to, "air-space disease," "focal opacification," "patchy areas of increased density." Although perhaps not specifically delineated as pneumonia by the radiologist, in the appropriate clinical setting these alternative descriptive wordings should be seriously considered as potentially positive findings. If provided and the findings are not documented as attributed to another issue (for example, pulmonary edema, chronic lung disease), they are eligible for meeting imaging test evidence of pneumonia.

20



21



- Subsequent imaging findings are definitive for pneumonia
 - Verifies the equivocal finding is <u>representative of pneumonia</u> and that there is <u>persistence</u>, making the equivocal finding <u>eligible for use</u>, OR
- Subsequent imaging findings no longer show pneumonia
 - Verifies the finding is <u>not representative of pneumonia</u>, making the equivocal finding <u>not eligible for use</u>

22

24



If the imaging does not demonstrate findings of pneumonia, clinical correlation cannot be used




^{14.} If the imaging test result is equivocal for pneumonia, check to see if subsequent imaging tests are definitive. For example, if a chest imaging test result states infiltrate vs. atelectasis and a subsequent imaging test result is definitive for infiltrate, the initial imaging test would be eligible for use. In the absence of finding a subsequent imaging result that clarifies the equivocal finding, if there is clinical correlation (see <u>Chapter 16</u>) then the equivocal imaging test is eligible for use.


IMAGING REPORTS

- Documentation of the radiologist's review of the imaging test
- Imaging reports typically contain 'findings' and 'impressions'
 - Findings = what the radiologist saw
 - Impressions = the radiologist's assessment of what the findings represent
- Both the findings and impressions must be considered when determining if the imaging test results are eligible for use in meeting PNEU

25




27




IMAGING EVIDENCE OF PNEUMONIA SUMMARY


- Findings must be new and persistent OR progressive and persistent
- Simply finding words such as infiltrate, consolidation, opacity, or airspace disease in an imaging test report is not enough
- Unlike imaging for other NHSN events, due to the persistence requirement, all available imaging findings that are temporally related must be considered
- Only definitive and equivocal findings are eligible for consideration
- Additional guidance can be found in the PNEU protocol (p. 6-3) under "Guidance for Determination of Eligible Imaging Test Evidence"

26






Signs/Symptoms	Laboratory	
At least one of the following: • Fever (38.0°C or >100.4°F) Leukopenia (24000 WBC/mm ³) or leukocytosis (212,000 WBC/mm ³) For adults 270 years old, altered mental status with no other recognized cause And at least one of the following: • New onset of purulent sputum ³ or change in character of sputum ⁴ , or change in character of sputum ⁴ , or change in character of sputum ⁴ , or increased suctioning requirements • New onset or worsening cough, or dyspnea, or tachypnea ³ • Rales ⁴ or bronchial breath sounds • Worsening gas exchange (1e.0, 240); increased oxygen requirements or ventilator demand)	At least one of the following: • Organism identified from blood ⁹ , ¹³ • Organism identified from pleural fluid ⁹ , ¹⁹ • Positive quantitative culture or corresponding semi-quantitative culture result ⁹ , from minimally-contaminated LRT specimen brushing or endotracheal aspirate) • 5% BAL-obtained cells contain intracellular bacteria on direct microscopic exam (i.e., gram stain) • Positive quantitative culture or corresponding semi-quantitative culture result ⁹ of lung lissue • Histopathologic exam shows at least one of the following evidences of pneumonia: Abscess formation or foci of consolidation with intense PMA accumulation in branchioles and alvelio Evidence of lung parenchyma invasion by fungal hyphae or pseudohyphae	TABLE 2: PNU2 S/S AND Specific Laboratory Findings (PNU2)
		Sales free





33



PATHOGEN EXCLUSIONS

- > All Candida species or yeast not otherwise specified
- ► All coagulase-negative Staphylococcus species
- ► All Enterococcus species
- Excluded as a <u>site-specific pathogen unless</u> isolated from *lung tissue or pleural fluid*

STOP

If identified from <u>blood</u>, the excluded pathogens can **only** be attributed as secondary to PNEU if PNU2 or PNU3 is met with a <u>matching organism</u> isolated from <u>lung tissue or pleural fluid</u> and the blood specimen is collected in the secondary BSI attribution period.



- Purulent sputum must meet definition in footnote #3. Documentation of "purulent" does not meet criteria. See Table on page 6-13 for guidance
- 3. Purulent sputum is defined as secretions from the lungs, bronchi, or trachea that contain ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field (x100). Refer to the table below if your laboratory reports these data semi-quantitatively or uses a different format for reporting Gram stain or direct examination results (for example, "many WBCs" or "few squamous epithelial cells"). This laboratory confirmation is required since written clinical descriptions of purulence are highly variable.

Table 5: Threshold values for cultured pneumonia	
Specimen collection/technique	Values*
Lung tissue†	≥ 10 ⁴ CFU/g tissue
Bronchoscopically (B) obtained specimens	
Bronchoalveolar lavage (B-BAL)	≥ 10 ⁴ CFU/ml
Protected BAL (B-PBAL)	≥ 10 ⁴ CFU/ml
Protected specimen brushing (B-PSB)	≥ 10 ³ CFU/ml
Nonbronchoscopically (NB) obtained (blind) specie	
NB-BAL	≥ 10 ⁴ CFU/ml
NB-PSB	≥ 10 ³ CFU/ml
Endotracheal aspirate (ETA)	≥ 10 ^s CFU/ml
thresholds. In the absence of additional informatio	rted semi-quantitative results match the quantitativ n available from your laboratory, a semi-quantitativ nerous" growth, or 2+, 3+, or 4+ growth is considere
*Lung tissue specimens obtained by either open or specimens, only lung tissue specimens obtained by collected immediately post-mortem are eligible for	transthoracic or transbronchial biopsy that are

KEY POINTS ON SIGNS/SYMPTOMS

Tachypnea, footnote #5: documented respiratory rate must meet the age-based parameters; documentation of "tachypnea" does not meet the criteria
 In adults, tachypnea is defined as respiration rate > 25 breaths per minute. Tachypnea is defined as > 75 breaths per minute in premature infants born at < 37 weeks gestation and until the 40th week; > 60 breaths per minute in patients < 2 months old; > 50 breaths per minute in patients 2.12 months old; and > 30 breaths per minute in children > 1 year old.

38

KNOWLEDGE CHECK # 3


▶ Within the 7-day IWP, there is :

- definitive imaging test evidence suggestive of pneumonia,
- the patient has leukocytosis,
- there is documentation of dyspnea and rales, and
- E. faecalis is identified from a BAL specimen

What is identified?

- 1. PNU1
- 2. PNU2
- 3. PNU3
- 4. None

39



PNEUMONIA & SECONDARY BSI

A PNEU site-specific definition must be met

AND

One of the following scenarios must be met: *Scenario 1:*


 At least one organism from the blood specimen matches an organism identified from the site-specific infection that is used as an element to meet the PNEU criterion AND the blood specimen is collected during the secondary BSI attribution period, OR

Scenario 2:

 An organism identified in the blood specimen is an element that is used to meet PNEU criterion, and therefore is collected during the site-specific IWP.

40


<text><list-item><list-item><list-item><list-item>





VAE TOOLS VAE Calculator and Worksheets

45



DEFINITIONS Ventilator: a device used to support, assist, or control respiration (inclusive of the weaning period) through the application of positive pressure to the airway when delivered via an artificial airway, specifically oral/nasal endotracheal or tracheostomy tube. ▶ Note: Ventilation and lung expansion devices that deliver positive pressure to the airway (for example, CPAP, BiPAP, Bilevel, IPPB, and PEEP) via non-invasive means (for example, nasal prongs, nasal mask, full face mask, total mask, etc.) are not considered ventilators unless positive pressure is delivered via an artificial airway (oral/nasal endotracheal or

WHY PERFORM VAE SURVEILLANCE

- ▶ 2015 CDC point-prevalence survey determined that of the 427 healthcare- associated infections identified in a sample of acute care hospitals in the U.S., pneumonia was the most common infection, with 35% of those being ventilator associated*
- > Other adverse events may occur to ventilated patients: Acute Respiratory Distress Syndrome (ARDS), sepsis, pulmonary embolism, barotrauma, pulmonary edema *Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of healthcare-associated infections in US hospitals. New England Journal of Medicine 2018; 379:1732-1744.

48

tracheostomy tube).

VENTILATOR ASSOCIATED EVENT (VAE)

- An adverse event "associated" with the use of a mechanical ventilator
- Detection of VAE may be related to:
 - Infection -respiratory or another site
 - Fluid overload
 - ARDS
 - Atelectasis
 - Provider preference in adjusting settings
 - Other
- "Surveillance is information for action"
 - Address duration of mechanical ventilation
- Address issues found to be "associated" with VAE detection

49

VAE SURVEILLANCE INCLUSION CRITERIA-SETTINGS

- Inpatient locations eligible to participate in VAE surveillance are those <u>adult locations</u> in acute care hospitals, long term acute care hospitals, and inpatient rehabilitation facilities where denominator data (ventilator days and patient days) can be collected for patients.
- Pediatric patients in adult locations are included in VAE surveillance

VAE ≠VAP(PNEU) & PVAP ≠VAP(PNEU)

- VAE and PNEU protocols detect two separate and distinct events.
 - It is possible to meet VAE and PNEU
 - It is possible to meet VAE and not PNEU
 - It is possible to meet PNEU and not VAE
 - May not meet either!
- Educate your clinicians to dispel the myth!
- VAE is designed to detect more than VAP

VAP –Ventilatorassociated Pneumonia (PNEU definition) PVAP–Possible Ventilatorassociated Pneumonia (VAE definition) NOTE: Both VAE and PNEU are available for secondary BSI assignment when conducting BSI

surveillance

50

VAE SURVEILLANCE EXCLUSION CRITERIA

- Patients on high frequency ventilation (HFV), paracorporeal membrane oxygenation, or extracorporeal life support (ECLS) are not eligible for VAE surveillance (during the time they are receiving those therapies)
- Patients in non-acute care locations in an acute care setting (such as a chronic care unit)
- Adults in pediatric locations are included in pedVAP surveillance

52

- Patients must be mechanically ventilated for more than 2 calendar days to be eligible for VAE
- The first two days of ventilation can be used to establish the baseline period of stability or improvement, but the earliest date of event for VAE is day 3 of mechanical ventilation



ADJUNCT THERAPIES & ALTERNATIVE MODES OF MECHANICAL VENTILATION

► VAE surveillance

- Includes patients who are receiving a conventional mode of mechanical ventilation:
 - While in the prone position
 - While receiving nitric oxide therapy, helium-oxygen mixtures (heliox), or epoprostenol therapy
- Includes patients on Airway Pressure Release Ventilation (APRV) or related modes
 - A mode of mechanical ventilation characterized by continuous application of positive airway pressure with an intermittent pressure release phase
 - Other names: BiLevel, Bi Vent, BiPhasic, PCV+, DuoPAP

EPISODE OF MECHANICAL VENTILATION


- A period of days during which the patient was mechanically ventilated for some portion of each consecutive day.
- ► A break in mechanical ventilation of at least one full calendar day, followed by reintubation and/or re-initiation of mechanical ventilation during the same hospitalization, defines a new episode of mechanical ventilation.

VAE ALGORITHM

- VAE is NOT a clinical definition and NOT intended for use in the management of patients
- NHSN Chapter 2 Definitions on identifying HAIs <u>do not</u> <u>apply to VAE</u>


Concept	SSI	LabID	VAE	PedVAE
Infection Window Period	Applicable Applicable		a	e.
Date of Event			lde	abl
Present on Admission	Olic L	olic	Not Applicable	Not Applicable
Healthcare-associated Infection	Apr	Not Applicable		
Repeat Infection Timeframe	Not			
Secondary BSI Attribution Period	Z	z		


56




57

55








OXYGENATION

- Patient's oxygenation needs can be addressed by adjusting the FiO₂ and/or PEEP settings on the ventilator
- ▶ FiO₂: fraction of oxygen in inspired air
 - Ex: FiO2 of room air is 0.21
 - Oxygenation concentration of room air is 21%
 - ▶ 0.21 = 21%
- ▶ PEEP: positive end-expiratory pressure
 - PEEP is the alveolar pressure above atmospheric pressure at the end of exhalation
 - Achieved by introduction of mechanical impedance to exhalation
 - Expressed in cmH₂O

61



DAILY MINIMUM FIO₂ & PEEP

- Daily minimum FiO₂: lowest value of FiO2 during a calendar day that is set on the ventilator and maintained for > 1 hour
- Daily minimum PEEP: lowest value of PEEP during a calendar day that is set on the ventilator and maintained for > 1 hour
 - Daily minimum PEEP values of 0-5 cmH2O are considered equivalent (equal to 5 cmH2O) for the purposes of VAE surveillance.

63

ELIGIBLE FIO, & PEEP SETTINGS

- The daily minimum FiO₂ and PEEP values are determined using all eligible FiO₂ and PEEP settings that are documented throughout the calendar day during times when the patient is receiving support from <u>an eligible mode of mechanical</u> <u>ventilation</u> in an <u>inpatient location</u>
- All conventional mechanical ventilation settings are to be used
 - Include settings collected during weaning/mechanical ventilation liberation trials if the patient is receiving ventilator support during those trials
 - Include conventional MV settings during times when a patient is intermittently on an excluded mode of ventilation or support throughout a calendar day
 - Do NOT include settings from the Emergency Department or other prehospital/pre-inpatient locations

64

INELIGIBLE FIO₂ & PEEP SETTINGS

Settings not eligible for use

- Periods of time when the patient is on high frequency ventilation, extracorporeal life support or paracorporeal membrane oxygenation.
- Periods of time when the patient is not receiving mechanical ventilation support (for example, a T-piece trial, or a trach collar trial, where the patient continues to receive supplemental oxygen, but is receiving no additional support from the mechanical ventilator).
- Periods of time when the patient is being mechanically-ventilated using APRV or a related strategy (for example, BiLevel, BiVent, BiPhasic, PCV+ and DuoPAP)
 - In these cases, only review FiO2 data (PEEP settings are not eligible for use).

DETERMINING DAILY MINIMUM FIO₂ AND PEEP

- From the eligible documented settings, use the lowest FiO₂ and PEEP setting during the calendar day that was maintained for greater than 1 hour
- In the event there is no value that has been maintained for greater than 1 hour, then select the lowest value available regardless of the period of time in which the setting was maintained
- When might there be no FiO2 and PEEP setting during the calendar day that was maintained for greater than 1 hour?
 - Ventilation initiated late in the calendar day
 - Ventilation discontinued early in the calendar day
 Ventilator settings very unstable throughout the day

GUIDANCE FOR DETERMINING DAILY MINIMUM PEEP AND FIO2-WHEN SETTINGS ARE RECORDED EVERY HOUR OR MORE FREQUENTLY

Specific guidance is found in the protocol

- There must be sufficient documentation of consecutive recordings to meet the minimum required duration of > 1 hour
 - If tracking every <u>15 minutes</u>, 5 consecutive recordings at the same setting would be needed (e.g., at 09:00, 09:15, 09:30, 09:45 and 10:00)
 - If tracking every <u>30 minutes</u>, 3 consecutive recordings at the same setting would be needed (e.g., at 09:00, 09:30, and 10:00)
 - If tracking every hour, 2 consecutive recordings at the same setting would be needed (e.g., at 09:00 and 10:00)
- Provides standardization

67

EVIDENCE OF WORSENING OXYGENATION

- After an identified period of stability or improvement there is evidence of worsening oxygenation in the <u>same</u> <u>parameter</u>
- Increase in daily minimum<u>* FiO2 of ≥ 0.20 (20 points)</u> over the daily minimum FiO2 of the first day in the baseline period, sustained for ≥ 2 calendar days.

OR

► Increase in daily minimum<u>* PEEP values of ≥ 3 cmH20</u> over the daily minimum PEEP of the first day in the baseline period⁺, sustained for ≥ 2 calendar days

*Daily minimum defined by lowest value of FiO2or PEEP during a calendar day that is maintained for > 1 hour.
*Daily minimum PEEP values of 0-5 cmH2O are considered equivalent for the purposes of VAE surveillance.

69

BASELINE PERIOD

- A baseline period of stability or improvement is defined by ≥ 2 calendar days of stable or decreasing daily minimum FiO2 values or stable or decreasing daily minimum PEEP values.
- The baseline period is defined as the two calendar days immediately preceding the first day of increased daily minimum FiO2 or PEEP (or, evidence of worsening oxygenation)

68

KEY POINTS FOR MEETING VAC DEFINITION

- Use the daily minimum FiO2 and PEEP values when assessing for both the period of stability or improvement and the period that indicates worsening oxygenation
- Do not compare values that occur within a calendar day to determine stability, improvement, or worsening.
- The baseline period and the evidence of worsening oxygenation must occur in the same parameter
- Each parameter is assessed independently of the other VAC may be met in the FiO2 parameter, or in the PEEP parameter, or in both parameters

70

DATE OF EVENT

- ► The date of onset of worsening oxygenation (day 1 of the required ≥ 2-day period of worsening oxygenation following a ≥ 2-day period of stability or improvement on the ventilator).
 - It is not the date on which all VAE criteria are met.
 - **•** It is not the date of the first day of the baseline period.
- Earliest date of event for VAE is mechanical ventilation day 3 (first day of worsening oxygenation)
- First possible day that VAC criteria can be <u>fulfilled</u> is mechanical ventilation day 4


WHY IS THE DATE OF EVENT IMPORTANT?

Defines the VAE Window Period

▶ Period during which criteria for other events—IVAC, PVAP—must be met


Sets the VAE 14-day Event Period

- Day 1 is the Date of Event—so if June 1 is date of onset of worsening oxygenation and a VAC is reported, a second VAE cannot be detected and reported until June 15.
- May not "upgrade" a VAE based on data collected outside the VAE Window Period but within the 14-day event period.
- May not report a new VAE until that 14-day period has elapsed (keep in mind that 14day period is event date to event date—so baseline period can occur during previous event period).
- Blood cultures must be collected within the 14-day event period for a BSI to be secondary to VAE



	Calculate VAC Start Over				
MV Day	Date	Min. PEEP (cmH ₂ O)	Min. FiO ₂ (21 - 100)	VAE	
1	2/1/2023	8	30		Period of
2	2/2/2023	8	30		stability
3	2/3/2023	8	30		for greater than 2 calendar days
4	2/4/2023	8	55		Increase from
5	2/5/2023	8	55		baseline maintaine for at least 2
6	2/6/2023	8	60		calendar days
-		1			


75




VAE WINDOW PERIOD: IMPORTANT NOTE

- There is an exception in which the VAE Window Period is only 3 or 4 days
- In cases where the VAE event date corresponds to mechanical ventilation (MV) day 3 or day 4, the VAE Window Period may only be a 3-day or a 4-day window, because it can NOT include any days before the 3rd day of MV
 - If the VAE event date is MV day 3, then the window period includes only the day of VAE onset and the 2 days after VAE onset (because the 2 days before VAE onset are before the 3rd day of MV).
 - If the VAE event date is MV day 4, then the window period includes only the day before, the day of, and the 2 days after the day of VAE onset







KEY DEFINITIONS

New antimicrobial agent: any agent listed in Appendix A (List of Antimicrobial Agents eligible for IVAC, PVAP) that is <u>initiated</u> on or after the third calendar day of mechanical ventilation <u>AND</u> in the VAE window period.

- Agent is considered new if it was <u>NOT</u> given to the patient on either of the 2 days preceding the current start date
- New agent must be administered IV, IM, or via digestive tract or respiratory tract
- New agent must be continued for ≥ 4 qualifying antimicrobial days

79

QUALIFYING ANTIMICROBIAL DAY (QAD)

- QAD: a day on which the patient was administered an antimicrobial agent that was determined to be "new" within the VAE Window Period.
- Four consecutive QADs are needed to meet the IVAC antimicrobial criterion
 - Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations.
 - There is no requirement that the <u>same</u> antimicrobial agent be given on the 4 qualifying antimicrobial days
 - QADs can accrue outside the VAE window period (<u>after</u> date of event)


80

FAQ: Do you count an antimicrobial agent as "new" if it is new as a result of de-escalation or simply a switch from one agent to another in the same drug class?

Yes


To avoid additional substantial complexity, there are not rules or exceptions for changes that represent narrowing of spectrum/de-escalation, switches to other agents in the same class, etc. These kinds of situations are very difficult to operationalize in a way that is understandable, standardized, and implementable by any facility that might decide to do VAE surveillance.

81





- Meeting the IVAC definition does not mean that the "infection related" event is necessarily respiratory in origin
- The IVAC antimicrobial list was refined by removing selected antimicrobial agents that would not be used, or would be unlikely to be used, in treating a lower respiratory infection in a critically ill patient
 - It is still possible that an existing agent may have dual purposes and not necessarily be used to treat a respiratory infection
- No need to discern the reason for the administration of the antimicrobial
 - Prophylaxis, de-escalation, change within a class of antimicrobials, etc. is not a reason for exclusion




PVAP - CRITERION 1

Positive culture of one of the following specimens, meeting quantitative <u>or</u> semi-quantitative thresholds as outlined in protocol, <u>without</u> requirement for purulent respiratory secretions:

- Endotracheal aspirate (ETA), ≥ 10^s CFU/ml or corresponding semi-quantitative result
- Bronchoalveolar lavage (BAL) ≥104 CFU/ml or corresponding semi-quantitative result
- Lung tissue, <u>>10</u>, CFU/g or corresponding semiquantitative result
- Protected specimen brush (PSB), ≥10³ CFU/ml or corresponding semi-quantitative result

85



87



SEMI-QUANTITATIVE CULTURE RESULTS

- FAQ: How do I relate my lab's semi-quantitative culture result reporting to the quantitative thresholds in the algorithm?
- Ask your laboratory manager/director they may be able to provide guidance
- If you lab does not have this information:
 - For the purposes of VAE surveillance, a semi-quantitative result of "moderate" "many" "numerous" or "heavy" growth, or 2+, 3+ or 4+ growth, meets the PVAP definition (Criterion 1).
 - See FAQ no. 24 in the VAE Protocol

86

GRAM STAINS

- FAQ: What if my lab reports Gram stain/direct exam results in a manner that doesn't quantitate neutrophils and squamous epithelial cells as the definition is written?
 - Check with the lab for direction in interpreting your facility's reporting method
 If your lab constant provide guidance refer to Table 2 or FAO pp. 10 in the VAE.
 - If your lab cannot provide guidance, refer to Table 2 or FAQ no. 19 in the VAE protocol

88

PVAP – CRITERION 3

One of the following positive tests:

- Pleural fluid culture (where specimen was obtained during thoracentesis or initial placement of chest tube and <u>NOT</u> from an indwelling chest tube)
- Lung histopathology, defined as:
 - 1) abscess formation or foci of consolidation with intense neutrophil accumulation in bronchioles and alveoli
 - 2) evidence of lung parenchyma invasion by fung
 - 3) evidence of infection with viral pathogens listed below based on results of immunohistochemical assays, cytology, or microscopy performed on lung tissue

PVAP – CRITERION 3, CONT.

One of the following positive tests:

- Diagnostic test for *Legionella* species
- Diagnostic test on respiratory secretions for influenza virus, RSV, adenovirus, parainfluenza virus, rhinovirus, human metapneumonovirus, coronavirus

91

Specimen collection/technique	Values			
Lung tissue	≥ 10 ⁴ CFU/g tissue*			
Bronchoscopically (B) obtained specimens	2			
Bronchoalveolar lavage (B-BAL)	≥ 10 ⁴ CFU/mI*			
Protected BAL (B-PBAL)	≥ 10 ⁴ CFU/ml*			
Protected specimen brushing (B-PSB)	≥ 10 ³ CFU/mI*			
Nonbronchoscopically (NB) obtained (blind) speci	mens			
NB-BAL	≥ 10 ⁴ CFU/ml*			
NB-PSB	$\geq 10^3 \text{CFU/ml}^*$			
Endotracheal aspirate (ETA)	≥ 10 ⁵ CFU/mI*			
U = colony forming units, g = gram, ml = milliter r corresponding semi-quantitative result (see FAQ no. 24 at the end	of this protocol)			

93

PATHOGEN EXCLUSIONS


- "Normal respiratory flora," "normal oral flora," "mixed respiratory flora," "mixed oral flora," "altered oral flora" or other similar results indicating isolation of commensal flora of the oral cavity or upper respiratory tract
- Candida species or yeast not otherwise specified, coagulase-negative Staphylococcus species, and Enterococcus species only available for use as PVAP pathogens when isolated from lung tissue or pleural fluid
 - Cannot be used to meet PVAP definition when identified from sputum, endotracheal aspirates, bronchoalveolar lavage, or protected specimen brushings

92

PEDVAE SURVEILLANCE

- In mid-2013, working group determined that there were insufficient data to inform development of a pediatric VAE definition.
- Further working group discussions were postponed until 2015, following publication of the results of a study on pediatric VAE definition criteria.
- This study demonstrated that events defined by changes in the fraction of inspired oxygen (FiO2) and Mean Airway Pressure (MAP) were associated with increases in patient length of stay as well as mortality.

94





PEDVAE SURVEILLANCE

- After additional discussion with the working group, CDC decided to move forward with pediatric VAE (PedVAE) development and implementation in NHSN.
- PedVAE field testing conducted in 2017
- PedVAE made available as an NHSN surveillance event starting in Jan. 2019

PEDVAE: ELIGIBLE PATIENTS

- Ventilated inpatients in acute care hospitals, long term acute care hospitals, inpatient rehabilitation facilities
- Patients in neonatal and pediatric locations where denominator data (ventilator and patient days) can be collected
 - Ventilated adults in pediatric locations are included in PedVAE surveillance regardless of age

97

PEDVAE: INELIGIBLE PATIENTS

- Patients on extracorporeal life support or paracorporeal membrane oxygenation are not eligible for VAE surveillance
 - Ineligibility only applies to periods of time while receiving this form of support
- Patients in non-acute care locations in acute care facilities (such as a chronic care unit)
- Pediatric patients in adult inpatient locations
 - Ventilated pediatric patients in adult locations are included in adult VAE surveillance


99

Includes patients on High Frequency Oscillatory or Jet Ventilation Airway Pressure Release Ventilation (APRV) Includes patients who are receiving mechanical ventilation while also receiving Proning Surfactant Corticosteroids Nitric oxide therapy Helium-oxygen mixture (heliox)

OTHER INCLUSION CRITERIA

Epoprostenol therapy

98



100

PEDVAE DETERMINATION

- PedVAEs are determined by identification of deterioration in respiratory status after a period of stability or improvement on the ventilator
- Assessed by monitoring two key parameters that reflect oxygenation status in neonatal and pediatric ventilated patients:
 - Fraction of Inspired Oxygen FiO₂
 - Mean Airway Pressure(MAP): average pressure exerted on the airway and lungs from the beginning of inspiration until the beginning of the next inspiration (inspiratory cycle)

MAP: MEAN AIRWAY PRESSURE

- MAP is a measured/calculated value (not a ventilator setting) that is determined by
 - ▶ PEEP Positive End-Expiratory Pressure
 - PIP Peak Inspiratory Pressure
 - Inspiratory time
 - Frequency

MEETING PEDVAE DEFINITION

- Patients must be mechanically ventilated for some portion of the day for at least 4 consecutive calendar days to fulfill PedVAE criteria (where the day of intubation or initiation of mechanical ventilation is day 1)
 - At least 2 days of stability or improvement
 - At least 2 days of evidence of worsening oxygenation
- The period of stability or improvement and the evidence of worsening oxygenation must occur in the same parameter
 - Each parameter is assessed independently of the other PedVAE may be met only in the FiO2 parameter, only in the MAP parameter, or in both parameters

103

PEDVAE DETERMINATION: FIO₂

A baseline period of stability or improvement in the FiO_2 parameter is immediately followed by an increase in the daily minimum FiO2 of ≥ 0.25 (25 points) over the daily minimum FiO2 of the first day in the baseline period that is sustained for ≥ 2 calendar days

104

PEDVAE DETERMINATION: MAP

A baseline period of stability or improvement in the MAP parameter is immediately followed by an increase in the daily minimum MAP of $\ge 4 \text{ cmH}_2\text{O}$ over the daily minimum MAP of the first day in the baseline period that is sustained for ≥ 2 calendar days

105

IMPORTANT NOTES ON MAP AND AGES

- In patients <30 days old, MAP values of 0-8 cmH₂O are considered equivalent, therefore would be assigned a daily minimum values of 8
 - An increase in the daily minimum MAP to at least 12, sustained for 2 calendar days, would be needed to meet the PedVAE definitions
- Patients ≥ 30 days old, MAP values of 0-10 cmH₂O are considered equivalent, therefore would be assigned a daily minimum value of 10
 - An increase to at least 14, sustained for 2 calendar days would be needed to meet the PedVAE definition

106

DATE OF EVENT

► The date of onset of worsening oxygenation (day 1 of the required ≥ 2-day period of worsening oxygenation following a ≥ 2-day period of stability or improvement on the ventilator)

- Earliest date of event for PedVAE is mechanical ventilation day 3 (first day of worsening oxygenation)
- The first two days of mechanical ventilation can establish the baseline period

14 DAY EVENT PERIOD

- PedVAEs are defined by a 14-day period
- The Date of Event is day 1 of the 14-day Event Period
 - A new PedVAE cannot be reported until the 14-day period has elapsed
 - For example, if a PedVAE is reported with a date of event March 1, this sets a 14-day event period March 1 - 14, and the earliest date a new PedVAE can be detected and reported is March 15
 - The 2 days of stability or improvement for a new PedVAE can occur during the previous 14-day event period

